Pfizer’s Dividend Appears Well-Supported Despite Patent-Cliff Risks

Key Points

• Pfizer’s leadership continues to emphasize its commitment to preserving the dividend.

• The company’s newer growth assets are helping offset pressure from patent expirations.

• Pfizer’s cash reserves add another layer of support for the dividend program.

Pfizer (NYSE: PFE) currently offers a forward dividend yield above 6.2%. Only a small number of S&P 500 (SNPINDEX: ^GSPC) companies provide a higher yield.

Pfizer’s dividend certainly faces meaningful questions as the company navigates a difficult period of patent expirations. Even so, the payout does not appear to be in immediate danger. Here are three reasons the dividend should be able to endure.

Image source: Getty Images.

1. Management has repeatedly backed the dividend

Pfizer CEO Albert Bourla made the company’s position clear during its second-quarter earnings call in August, saying, “We remain committed to maintaining and, over time, growing our dividend.” That message is consistent with comments he has made previously.

Interim CFO Cecile Guegan also referenced the dividend several times during her financial update. She emphasized that Pfizer intends to keep paying dividends while continuing to invest in growth opportunities.

Perhaps the strongest signal came when Morgan Stanley (NYSE: MS) analyst Terence Flynn asked Bourla what would need to happen for Pfizer to consider reducing the dividend. Bourla said management is “extremely confident that we will — even the most stretched scenarios that we are running — we will be able to maintain our dividend.” He also said he wanted to make the point clear “once and for all” that Pfizer would maintain the payout and eventually restore dividend growth.

Management commentary is not a guarantee, and companies can change course if conditions deteriorate. Still, Bourla’s language was unusually direct, suggesting leadership does not currently view a dividend cut as a likely outcome.

2. The growth portfolio is helping offset patent pressure

Much of the concern around Pfizer’s dividend stems from the company’s patent cliff. Several major products are losing exclusivity, which could pressure revenue in the coming years. However, Pfizer’s growth portfolio appears to be making progress in offsetting some of that expected decline.

The company has surpassed revenue expectations in nine of the past 10 quarters. It has also beaten adjusted earnings estimates in all 10 quarters.

In the second quarter, acquired products contributed about one-fourth of Pfizer’s operating revenue growth. Therapies gained through the Seagen acquisition delivered 21% year-over-year operating revenue growth. Meanwhile, operating revenue for Nurtec, the migraine treatment Pfizer gained through its Biohaven acquisition, rose 17%.

Pfizer continues to project a high single-digit compound annual growth rate in revenue over the next five years. Newer products will be important to achieving that target, including berobenatide, the promising weight-loss drug candidate added through the Metsera acquisition.

3. Pfizer has a meaningful cash reserve

Pfizer also has a sizable cash position, which strengthens its ability to maintain the dividend through the current transition. As of June 28, 2026, the company had roughly $11.7 billion in cash, cash equivalents, and short-term investments.

The company does not appear to be planning to use that cash primarily to reduce debt. Guegan said during the second-quarter call, “Given the LOE [loss of exclusivity] impact over the next few years, we expect leverage to remain around the current level or modestly higher through this transition period.”

Pfizer also does not seem likely to prioritize share repurchases in the near term. Guegan mentioned “reserving optionality for future value-enhancing actions, including share repurchases,” but she did not indicate that buybacks were imminent.

Pfizer could still use cash for business development, although Bourla told analysts that any additional acquisitions would likely be “bolt-on” deals rather than major transformations.

No dividend increase soon, but a cut does not look likely

Investors should not expect Pfizer to raise its dividend in the near term. Management’s comments about resuming dividend growth appear to point to a period after 2028. However, the current payout looks more secure than the headline risks might suggest.

Pfizer still faces a challenging stretch as multiple drugs lose exclusivity over the next few years. Even so, the company appears positioned to manage that transition while maintaining the dividend at its current level. For income investors who can tolerate above-average risk, Pfizer’s high yield and relatively low valuation may continue to make the stock worth considering.

Source link